122 related articles for article (PubMed ID: 38395156)
21. IL-7 is required for the development of the intrinsic function of marginal zone B cells and the marginal zone microenvironment.
Willems L; Li S; Rutgeerts O; Lenaerts C; Waer M; Billiau AD
J Immunol; 2011 Oct; 187(7):3587-94. PubMed ID: 21873520
[TBL] [Abstract][Full Text] [Related]
22. Carrier-free subunit nanovaccine amplifies immune responses against tumors and viral infections.
Chen H; Li Y; Li L; Yang Z; Wen Z; Liu L; Liu H; Chen Y
Acta Biomater; 2023 Mar; 158():525-534. PubMed ID: 36572250
[TBL] [Abstract][Full Text] [Related]
23. In vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity.
Villegas-Mendez A; Garin MI; Pineda-Molina E; Veratti E; Bueren JA; Fender P; Lenormand JL
Mol Ther; 2010 May; 18(5):1046-53. PubMed ID: 20179681
[TBL] [Abstract][Full Text] [Related]
24. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
[TBL] [Abstract][Full Text] [Related]
25. Targeted antigen delivery to dendritic cell via functionalized alginate nanoparticles for cancer immunotherapy.
Zhang C; Shi G; Zhang J; Song H; Niu J; Shi S; Huang P; Wang Y; Wang W; Li C; Kong D
J Control Release; 2017 Jun; 256():170-181. PubMed ID: 28414151
[TBL] [Abstract][Full Text] [Related]
26. Glycosylation of OVA antigen-loaded PLGA nanoparticles enhances DC-targeting for cancer vaccination.
Chou PY; Lin SY; Wu YN; Shen CY; Sheu MT; Ho HO
J Control Release; 2022 Nov; 351():970-988. PubMed ID: 36220488
[TBL] [Abstract][Full Text] [Related]
27. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.
Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K
J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727
[TBL] [Abstract][Full Text] [Related]
28. Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy.
Chen J; Fang H; Hu Y; Wu J; Zhang S; Feng Y; Lin L; Tian H; Chen X
Bioact Mater; 2022 Jan; 7():167-180. PubMed ID: 34466725
[TBL] [Abstract][Full Text] [Related]
29. H
Fan Y; Bai T; Tian Y; Zhou B; Wang Y; Yang L
Drug Des Devel Ther; 2021; 15():209-222. PubMed ID: 33488068
[TBL] [Abstract][Full Text] [Related]
30. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
[TBL] [Abstract][Full Text] [Related]
31. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
[TBL] [Abstract][Full Text] [Related]
32. Nanovaccine Incorporated with Hydroxychloroquine Enhances Antigen Cross-Presentation and Promotes Antitumor Immune Responses.
Liu J; Liu X; Han Y; Zhang J; Liu D; Ma G; Li C; Liu L; Kong D
ACS Appl Mater Interfaces; 2018 Sep; 10(37):30983-30993. PubMed ID: 30136844
[TBL] [Abstract][Full Text] [Related]
33. mIgM-mediated splenic marginal zone B cells targeting of folic acid for immunological evasion.
Wang H; Jiang Z; Guo Z; Luo G; Ding T; Zhan C
Acta Pharm Sin B; 2024 Feb; 14(2):808-820. PubMed ID: 38322341
[TBL] [Abstract][Full Text] [Related]
34. Self-adjuvanting cancer nanovaccines.
Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
[TBL] [Abstract][Full Text] [Related]
35. Intranasal immunization with poly(γ-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity.
Matsuo K; Koizumi H; Akashi M; Nakagawa S; Fujita T; Yamamoto A; Okada N
J Control Release; 2011 Jun; 152(2):310-6. PubMed ID: 21402114
[TBL] [Abstract][Full Text] [Related]
36. In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine.
Cayeux S; Bukarica B; Buschow C; Charo J; Bunse M; Dörken B; Blankenstein T
Gene Ther; 2007 Oct; 14(20):1481-91. PubMed ID: 17700709
[TBL] [Abstract][Full Text] [Related]
37. Hybrid mRNA Nano Vaccine Potentiates Antigenic Peptide Presentation and Dendritic Cell Maturation for Effective Cancer Vaccine Therapy and Enhances Response to Immune Checkpoint Blockade.
Shi L; Yang J; Nie Y; Huang Y; Gu H
Adv Healthc Mater; 2023 Dec; 12(32):e2301261. PubMed ID: 37822133
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cells that endocytosed antigen-containing IgG-liposomes elicit effective antitumor immunity.
Kawamura K; Kadowaki N; Suzuki R; Udagawa S; Kasaoka S; Utoguchi N; Kitawaki T; Sugimoto N; Okada N; Maruyama K; Uchiyama T
J Immunother; 2006; 29(2):165-74. PubMed ID: 16531817
[TBL] [Abstract][Full Text] [Related]
39. Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo.
Luo Z; Wang C; Yi H; Li P; Pan H; Liu L; Cai L; Ma Y
Biomaterials; 2015 Jan; 38():50-60. PubMed ID: 25457983
[TBL] [Abstract][Full Text] [Related]
40. Cancer Immunotherapy of TLR4 Agonist-Antigen Constructs Enhanced with Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1.
Traini G; Ruiz-de-Angulo A; Blanco-Canosa JB; Zamacola Bascarán K; Molinaro A; Silipo A; Escors D; Mareque-Rivas JC
Small; 2019 Jan; 15(4):e1803993. PubMed ID: 30569516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
